• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

抗菌肽 LL-37 促进肝癌细胞的 EMT、迁移和转移：体外和小鼠模型研究。

Cathelicidin LL-37 promotes EMT, migration and metastasis of hepatocellular carcinoma cells in vitro and mouse model.

机构信息

Jiangsu Province Key Laboratory for Molecular and Medical Biotechnology, Life Sciences College, Nanjing Normal University, Nanjing, Jiangsu, China.

出版信息

Cell Adh Migr. 2023 Dec;17(1):20-34. doi: 10.1080/19336918.2023.2168231.

DOI:10.1080/19336918.2023.2168231
PMID:36656313
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9858423/
Abstract

The effect of cathelicidin hCAP18/LL-37 in hepatocellular carcinoma (HCC) metastasis remains unclear. Here, we confirmed that LL-37 expression enhanced endothelial-mesenchymal transition (EMT), migration and invasion in HCC cells. And the HER2/EGFR-MAPK/ERK signal participated in the process above. More frequent lung metastases were observed in an LL-37-overexpressing hematogenous metastasis model. Interestingly, 1,25(OH)D together with si-LL-37 significantly enhanced 1,25(OH)D-induced inhibition of migration and invasion in PLC/PRF-5 cells, and also enhanced reversion of the EMT process. Therefore, LL-37 is involved in HCC metastases, and may act as an important factor to attenuate the inhibitory activity of 1,25(OH)D on HCC metastasis. Targeting hCAP18/LL-37 may offer a potential strategy to improve the anticancer activity of 1,25(OH)D in HCC therapy.

摘要

cathelicidin hCAP18/LL-37 在肝细胞癌 (HCC) 转移中的作用尚不清楚。在这里，我们证实 LL-37 表达增强了 HCC 细胞中的内皮-间充质转化 (EMT)、迁移和侵袭。HER2/EGFR-MAPK/ERK 信号参与了这一过程。在一个过表达 LL-37 的血源性转移模型中观察到更频繁的肺转移。有趣的是，1,25(OH)D 与 si-LL-37 一起显著增强了 1,25(OH)D 诱导的 PLC/PRF-5 细胞迁移和侵袭抑制，并且还增强了 EMT 过程的逆转。因此，LL-37 参与 HCC 转移，并且可能作为减弱 1,25(OH)D 对 HCC 转移抑制活性的重要因素。靶向 hCAP18/LL-37 可能为提高 1,25(OH)D 在 HCC 治疗中的抗癌活性提供一种潜在策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1de/9858423/6420077814b3/KCAM_A_2168231_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1de/9858423/c06dcb491fb3/KCAM_A_2168231_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1de/9858423/6a70dfe73ab0/KCAM_A_2168231_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1de/9858423/5d42bdffc69d/KCAM_A_2168231_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1de/9858423/95aca0380312/KCAM_A_2168231_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1de/9858423/3e7559acd2c1/KCAM_A_2168231_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1de/9858423/b75424f1d583/KCAM_A_2168231_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1de/9858423/6420077814b3/KCAM_A_2168231_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1de/9858423/c06dcb491fb3/KCAM_A_2168231_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1de/9858423/6a70dfe73ab0/KCAM_A_2168231_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1de/9858423/5d42bdffc69d/KCAM_A_2168231_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1de/9858423/95aca0380312/KCAM_A_2168231_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1de/9858423/3e7559acd2c1/KCAM_A_2168231_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1de/9858423/b75424f1d583/KCAM_A_2168231_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1de/9858423/6420077814b3/KCAM_A_2168231_F0007_OC.jpg

相似文献

1
Cathelicidin LL-37 promotes EMT, migration and metastasis of hepatocellular carcinoma cells in vitro and mouse model.抗菌肽 LL-37 促进肝癌细胞的 EMT、迁移和转移：体外和小鼠模型研究。
Cell Adh Migr. 2023 Dec;17(1):20-34. doi: 10.1080/19336918.2023.2168231.
2
Cathelicidin hCAP18/LL-37 promotes cell proliferation and suppresses antitumor activity of 1,25(OH)D in hepatocellular carcinoma.抗菌肽hCAP18/LL-37促进细胞增殖并抑制1,25(OH)D在肝细胞癌中的抗肿瘤活性。
Cell Death Discov. 2022 Jan 17;8(1):27. doi: 10.1038/s41420-022-00816-w.
3
Delphinidin inhibits epidermal growth factor-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma cells.飞燕草素抑制表皮生长因子诱导的肝癌细胞上皮-间质转化。
J Cell Biochem. 2019 Jun;120(6):9887-9899. doi: 10.1002/jcb.28271. Epub 2018 Dec 9.
4
FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.FoxM1过表达促进肝细胞癌的上皮-间质转化和转移。
World J Gastroenterol. 2015 Jan 7;21(1):196-213. doi: 10.3748/wjg.v21.i1.196.
5
JARID2 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelial-mesenchymal transition through PTEN/AKT signaling.JARID2通过PTEN/AKT信号通路促进上皮-间质转化，从而促进肝细胞癌的侵袭和转移。
Oncotarget. 2016 Jun 28;7(26):40266-40284. doi: 10.18632/oncotarget.9733.
6
MAP4K4 promotes epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma.MAP4K4促进肝细胞癌的上皮-间质转化和转移。
Tumour Biol. 2016 Aug;37(8):11457-67. doi: 10.1007/s13277-016-5022-1. Epub 2016 Mar 24.
7
HEG1 indicates poor prognosis and promotes hepatocellular carcinoma invasion, metastasis, and EMT by activating Wnt/β-catenin signaling.HEG1 通过激活 Wnt/β-catenin 信号通路促进肝癌侵袭、转移和 EMT，预示着不良预后。
Clin Sci (Lond). 2019 Jul 25;133(14):1645-1662. doi: 10.1042/CS20190225. Print 2019 Jul 31.
8
Upregulation of microRNA-140-3p inhibits epithelial-mesenchymal transition, invasion, and metastasis of hepatocellular carcinoma through inactivation of the MAPK signaling pathway by targeting GRN.上调 microRNA-140-3p 通过靶向 GRN 使 MAPK 信号通路失活，从而抑制肝癌的上皮-间充质转化、侵袭和转移。
J Cell Biochem. 2019 Sep;120(9):14885-14898. doi: 10.1002/jcb.28750. Epub 2019 May 1.
9
DEPTOR induces a partial epithelial-to-mesenchymal transition and metastasis via autocrine TGFβ1 signaling and is associated with poor prognosis in hepatocellular carcinoma.DEPTOR 通过自分泌 TGFβ1 信号诱导部分上皮间质转化和转移，并与肝细胞癌的不良预后相关。
J Exp Clin Cancer Res. 2019 Jun 22;38(1):273. doi: 10.1186/s13046-019-1220-1.
10
Jianpi Huayu decoction inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells by suppressing exosomal miR-23a-3p/Smad signaling.健脾化瘀汤通过抑制外泌体 miR-23a-3p/Smad 信号通路抑制肝癌细胞上皮-间充质转化。
J Ethnopharmacol. 2022 Aug 10;294:115360. doi: 10.1016/j.jep.2022.115360. Epub 2022 May 11.

引用本文的文献

1
LL37 promotes angiogenesis: a potential therapeutic strategy for lower limb ischemic diseases.LL37促进血管生成：一种治疗下肢缺血性疾病的潜在策略。
Front Pharmacol. 2025 Apr 23;16:1587351. doi: 10.3389/fphar.2025.1587351. eCollection 2025.
2
Regulation of the terminal complement cascade in adipose tissue for control of its volume, cellularity, and fibrosis.脂肪组织中终末补体级联反应的调节，以控制其体积、细胞组成和纤维化。
Obesity (Silver Spring). 2025 May;33(5):839-850. doi: 10.1002/oby.24270. Epub 2025 Mar 25.
3
The Role of Chemokine (C-C Motif) Ligand 7 (CCL7) in Hepatocellular Carcinoma: Expression, Function, and Mechanisms.

本文引用的文献

1
Cathelicidin Mediates an Anti-Inflammatory Role of Active Vitamin D (Calcitriol) During Infection.抗菌肽在活性维生素 D（骨化三醇）抗感染过程中发挥抗炎作用。
Front Cell Infect Microbiol. 2022 Apr 4;12:875772. doi: 10.3389/fcimb.2022.875772. eCollection 2022.
2
MMP9: A Tough Target for Targeted Therapy for Cancer.基质金属蛋白酶9：癌症靶向治疗的一个棘手靶点。
Cancers (Basel). 2022 Apr 6;14(7):1847. doi: 10.3390/cancers14071847.
3
Cathelicidin hCAP18/LL-37 promotes cell proliferation and suppresses antitumor activity of 1,25(OH)D in hepatocellular carcinoma.
趋化因子（C-C基序）配体7（CCL7）在肝细胞癌中的作用：表达、功能及机制
Cancer Med. 2025 Mar;14(5):e70701. doi: 10.1002/cam4.70701.
4
Mechanisms and therapeutic targets of ErbB family receptors in hepatocellular carcinoma: a narrative review.肝细胞癌中ErbB家族受体的机制及治疗靶点：一篇叙述性综述
Transl Cancer Res. 2024 Jun 30;13(6):3156-3178. doi: 10.21037/tcr-24-837. Epub 2024 Jun 27.
5
Cathelicidin Antimicrobial Peptide Acts as a Tumor Suppressor in Hepatocellular Carcinoma.抗菌肽 Cathelicidin 在肝细胞癌中作为肿瘤抑制因子发挥作用。
Int J Mol Sci. 2023 Oct 27;24(21):15652. doi: 10.3390/ijms242115652.
抗菌肽hCAP18/LL-37促进细胞增殖并抑制1,25(OH)D在肝细胞癌中的抗肿瘤活性。
Cell Death Discov. 2022 Jan 17;8(1):27. doi: 10.1038/s41420-022-00816-w.
4
Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression.基质金属蛋白酶在癌症进展中塑造肿瘤微环境。
Int J Mol Sci. 2021 Dec 23;23(1):146. doi: 10.3390/ijms23010146.
5
Recent advances in systemic therapy for hepatocellular carcinoma.肝细胞癌全身治疗的最新进展
Biomark Res. 2022 Jan 9;10(1):3. doi: 10.1186/s40364-021-00350-4.
6
Hepatocellular carcinoma: metastatic pathways and extra-hepatic findings.肝细胞癌：转移途径和肝外表现。
Abdom Radiol (NY). 2021 Aug;46(8):3698-3707. doi: 10.1007/s00261-021-03151-3. Epub 2021 Jun 5.
7
Frontiers of therapy for hepatocellular carcinoma.肝细胞癌治疗的前沿。
Abdom Radiol (NY). 2021 Aug;46(8):3648-3659. doi: 10.1007/s00261-021-03065-0. Epub 2021 Apr 10.
8
Vitamin D Regulates CXCL12/CXCR4 and Epithelial-to-Mesenchymal Transition in a Model of Breast Cancer Metastasis to Lung.维生素 D 调节乳腺癌肺转移模型中的 CXCL12/CXCR4 和上皮间质转化。
Endocrinology. 2021 Jul 1;162(7). doi: 10.1210/endocr/bqab049.
9
The In Vivo Selection Method in Breast Cancer Metastasis.体内乳腺癌转移的选择方法。
Int J Mol Sci. 2021 Feb 14;22(4):1886. doi: 10.3390/ijms22041886.
10
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.